• Profile
Close

Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug- eluting stent implantation in dialysis patients

Clinical Kidney Journal May 06, 2020

Park S, Kim Y, Jo HA, et al. - In view of the observation that end-stage renal disease yields susceptibility to both ischemia and bleeding and the reported benefits of prolonged dual antiplatelet therapy (DAPT) > 12 months in chronic kidney disease, researchers here examined the effectiveness and safety of prolonged DAPT in dialysis patients with higher cardiovascular risks. They conducted a nationwide population-based study including dialysis patients who underwent drug-eluting stent (DES) implantation from 2008 to 2015. They performed landmark analyses including free-of-event participants at 12 (n = 2,246), 15 (n = 1,925) and 18 months (n = 1,692) after DES implantation, to compare continued DAPT with discontinued DAPT. Depending on landmarks, mean follow-up periods of 278.3–292.4 days was reported. Overall, far lower incidences of major bleeding vs those of MACE were observed. Outcomes suggest reduction in MACE in correlation with receiving prolonged DAPT with no significant increase in major bleeding in patients who were event-free at 12 months after DES implantation. While deciding on DAPT duration, they recommend considering prolonged DAPT in dialysis patients.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay